Names and origins
What is Thymosin Alpha-1?
The definition, the manufactured drug and the closely named molecules that complicate the search.
Thymosin definition and the alpha-1 peptide
Thymosin Alpha-1 is a naturally occurring 28-amino-acid peptide involved in immune regulation. Amino acids are the units in the chain; their order identifies the molecule. Alpha-1 names one particular peptide within the broader thymosin family. The family name alone leaves the identity incomplete.
The body produces alpha-1 by cutting it from prothymosin alpha, a larger 113-amino-acid protein. The clinical review describes the peptide's immune effects and subsequent development as thymalfasin. I prefer starting with that chemical identity. It saves a surprising amount of confusion later.
The calf thymus and fraction 5
The 1977 isolation and sequence paper describes the purification of thymosin alpha-1 from calf thymus, in a mixture called thymosin fraction 5. Goldstein and colleagues established the complete 28-amino-acid sequence. The peptide has an acetylated N-terminus, a chemical modification at the beginning of the chain that is important for activity.
For this stocktake, the important step is the sequence: it lets me recognise the same molecule under a later drug name. The later synthetic drug copies that sequence. A 1990 report on U.S. thymosin trials records the clinical development already under way by then. This compound has a history that long predates its current online reputation.
Thymalfasin and TA1 peptide
Thymalfasin is the standard name for manufactured thymosin alpha-1. The synthetic and naturally occurring forms share the same amino-acid sequence. TA1, Tα1 and T-alpha-1 are shortened forms encountered in discussion of the peptide.
The comprehensive literature review reports thymalfasin approval in more than 35 countries, chiefly around chronic viral hepatitis and immune support. It has no FDA approval for marketing in the United States. A compounded preparation likewise has no FDA approval, even when a licensed clinician has assessed the case and issued a prescription.
The names identify the substance. They do not settle whether a proposed use has clinical support or whether a particular preparation meets patient-medicine standards.
Other thymosins
Thymosin beta-4 has 43 amino acids and is associated with tissue repair and cell movement. TB-500 is a shorter fragment associated with beta-4. Prothymosin alpha is the larger precursor of alpha-1. These names refer to distinct molecules and cannot be substituted for one another in a study summary.
The existing record distinguishes the sports prohibition covering beta-4 from alpha-1. That distinction offers no evidence for sporting benefit. Research on alpha-1 concerns immune function, with no sound evidence here of muscle growth, fat loss or improved athletic performance.
The clinical uses investigated
The clinical literature covers hepatitis B and C, sepsis, severe acute pancreatitis, COVID-19, HIV-related immune recovery, vaccine responses and cancer adjunct treatment. The strongest recurring efficacy signals in that summary concern chronic viral hepatitis. The largest sepsis trial found no significant mortality benefit.
My reason for pursuing the record is the possibility of a useful addition in a defined setting. That is enough to make the history interesting without assigning the peptide every benefit associated with the word immune. The trial inventory follows the accompanying treatments and the measured outcomes.